

Presentation to AGM 9 November 2011

Chris Fullerton
Chairman

Business Model



Technology platforms for drug discovery

Multiple drug candidates

Develop own products & out-license

Multiple revenue streams



MultiCore® Angene® ionX®



Cancer

Anxiety/
Depression
Multiple
Sclerosis



Clinical development of selected drugs to "Proof of Concept"

Partner with big Pharma



License fees

Milestone payments

Royalties

Development funding

Contract research

FY11 Highlights - Financial



- Revenue to 30 June 2011, excluding grants: \$4.07m
 - Another year of strong performance by Neurofit from contract research for big Pharma
- Increased investment in BNC105 & BNC210:
 - R&D expenses were \$9,096,660 compared to \$8,586,455 in the previous year
- Register re-positioning:
 - Start-up Australia Ventures sold 60m BNO shares at 57c to domestic & international institutions
- BNO institutional placement at 57c per share raised \$14.25m,
 2.5x covered
- Sold head office & research facility in Thebarton, SA for cash inflow of \$4.27m in July 2011
- Strong balance sheet provides Bionomics with strategic flexibility
 & strengthened position for partnering negotiations

FY11 Shareholder Value





Key Objectives for 2012



Our key objectives for the next year are:

- To partner our anxiety / depression drug BNC210.
- To increase the intensity and breadth of our trials on our cancer drug BNC105, with a view to building the most impressive database possible to be used for future partnering discussions.
- To expand and continue to develop our drug pipeline.